Pages that link to "Q38742278"
Jump to navigation
Jump to search
The following pages link to Inhalable lactose-based dry powder formulations of low molecular weight heparin. (Q38742278):
Displaying 9 items.
- Aerosol Delivery of siRNA to the Lungs. Part 1: Rationale for Gene Delivery Systems (Q28392004) (← links)
- Heparin and related drugs: beyond anticoagulant activity. (Q37105310) (← links)
- RNAi Therapeutic Platforms for Lung Diseases (Q37277373) (← links)
- Pulmonary delivery of therapeutic siRNA. (Q37847687) (← links)
- Non-anticoagulant Effects of Heparin: An Overview (Q38008270) (← links)
- Strategies for non-invasive delivery of biologics (Q38013190) (← links)
- The safety of ethambutol dihydrochloride dry powder formulations containing chitosan for the possibility of treating lung tuberculosis (Q38932441) (← links)
- Formulation of pH responsive peptides as inhalable dry powders for pulmonary delivery of nucleic acids. (Q39148199) (← links)
- Comparative studies on chitosan and polylactic-co-glycolic acid incorporated nanoparticles of low molecular weight heparin (Q39261905) (← links)